SOST and Stroke: Recently, the discontinuation of odanacatib (anti‐cathepsin K monoclonal antibody) over stroke concerns and the imbalance in ischemic events in romosozumab‐treated (anti‐sclerostin monoclonal antibody) women compared to bisphosphonate‐treated women, has provided further justification to better characterize potential CV benefits and harms of osteoporosis medications.